Bergua Burgués, Juan Miguel | Hematología y Hemoterapia

Resultados: 124
Tipo Título / Nombre Autor(es) Año
Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial Ayal RM, Rapado I, Martínez-Cuadron D, Onecha E, Rufian L, Juarez A, Bergua Burgues JM, Vives S, Algarra JL, Torno M, Martínez P, Serrano J, Herrera P, , Salamero O, Lavilla E, Gil C, López Lorenzo JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, l Pavia B, Barragán E, Prosper F, Sanz MA, Martínez López J, Montesinos Fernández P 2019
Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients Ribera JM, Garcia O, Cervera M, Rguez C, Sirvent M, Vall-Llovera F, Abrisqueta P, Serrano J, Buendía B, Montesinos Fernández P, Vives S, Bergua Burgues JM, Bastos-Oreiro MB, Acuña E, Moreno MJ, García Cardenas I, Terol MJ, Hernández Rivas JM, García Guiñon A, Herrera Puente P, Mercadasl S, Ivan I, Cladera A, Gimeno Vázquez E, Torrent A, Serrano-Maestro A, Barrenetxea C, García D, Arranz R, Sebrango A, Alonso N, Martínez-Carbelleira D, Sancho JM 2019
Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies Bogliolo M, Pujol R, Aza-Carmona M, Muñoz-Subirana N, Rodriguez-Santiago B, Casado JA, Rio P, Bauser C, Reina-Castillón J, Lopez-Sanchez M, Gonzalez-Quereda L, Gallano P, Catalá A, Ruiz-Llobet A, Badell I, Diaz-Heredia C, Hladun R, Senent L, Argiles B, Bergua Burgues JM, Bañez F, Arrizabalaga B, López Almaraz R, Lopez M, Figuera Á, Molinés A, Pérez de Soto I, Hernando I, Muñoz JA, Del Rosario Marin M, Balmaña J, Stjepanovic N, Carrasco E, Cuesta I, Cosuelo JM, Regueiro A, Moraleda Jimenez J, Galera-Miñarro AM, Rosiñol L, Carrió A, Beléndez-Bieler C, Escudero Soto A, Cela E, de la Mata G, Fernández-Delgado R, Garcia-Pardos MC, Sáez-Villaverde R, Barragaño M, Portugal R, Lendinez F, Hernadez I, Vagace JM, Tapia M, Nieto J, Garcia M, Gonzalez M, Vicho C, Galvez E, Valiente A, Antelo ML, Ancliff P, Garcia F, Dopazo J, Sevilla J, Paprotka T, Pérez-Jurado LA, Bueren J, Surralles J. 2019
Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study Chiappella A, Witzig E, Cocks K, Greenwood M, Williams A, Scott DW, Gascoyne RD, Yamamoto K, Jurczak W, Özcan M, Belada D, Bergua Burgues JM, Piazza F, Visco C, Musuraca G, Margunato Debay S, Czuczman M, Zhai M, Braverman J, Vitolo U, Nowakowski G 2019
Outcomes after Plerixafor Plus FLAG-IDA (PLERIFLAG) Versus FLAG-IDA +/- Gentuzumab for Adult Patients with First Relapsed/Refractory AML: A Propensity Score Analysis from the Pethema Registry Bergua Burgues JM, Cano-Ferri I, Martínez Cuadron D, Boluda B, Martínez Sánchez P, Rodríguez Veiga R, Esteve J, Vives S, Serrano J, Vidriales MB, Salamero O, Carretero C, Jiménez Ubieto A, Casas I, Cardesa R, Díaz Beyá M, Brunet S, benavente C, Pérez Simón JA, Moscardo F, Aguilar E, Pérez Encinas M, López Martínez A, Rodríguez C, Cabello A, Labrador J, Costilla L, Sossa C, Bernal del Castillo T, Sanz MA, Montesinos P 2019
Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Adult Patients with High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Acute Lymphoblastic Leukemia (ALL) According to Their Minimal Residual Disease (MRD). Final Results of the Pethema ALL-HR-11 Trial Ribera JM, Morgades M, Prob M, Ciudad J, Montesinos P, Barba P, García-Cadenas I, Moreno MJ, Vives S, Esteve J, Gil C, Monsalvo S, Artola MT, Ribera J, Genesca E, Tormo M, Cervera M, Martínez Carballeira D, Novo A, González Campos J, Soria B, Bermúdez A, López Martínez A, Mercadal S, Fernández Martín R, Coll R, Serrano J, Amigo ML, Martínez Sánchez P, Bergua JM, Serrano Maestro A, Giménez Conca A, Barrera S, Granada I, Feliu E, Orfao A 2019
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, Sanz MÁ 2019
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus Montesinos P, Bergua J, Infante J, Esteve J, Guimaraes JE, Sierra J, Sanz MÁ 2019
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols Sobas M, Rodriguez-Veiga R, Vellenga E, Paluszewska M, De la Serna J, García-Álvarez F, Gil C, Brunet S, Bergua J, González-Campos J, Ribera JM, Tormo M, González M, Fernández I, Benavente C, González-Sanmiguel JD, Esteve J, Pérez-Encinas M, Salamero O, Manso F, Lowenberg B, Sanzs MA, Montesinos P, PETHEMA, HOVON, PALG, GATLA cooperative groups 2019
Clinicobiologic characteristics and outcome of elderly frail patients with acute lymphoblastic leukemia included in a specific protocol (all-07FRAIL) Ribera JM, García Calduch O, Gil C, González Campos J, Moreno MJ, Barba P, Amigo ML, Martinez Carballeira D, Alonso N, Bergua JM, Mercadal S, Cladera A, Vall Llovera F, García Guinon A, López A, Lavilla E, Sierra M, Hernández Rivas JM 2019